Published: 2017-12-21 10:11:32 CET
Zealand Pharma
Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January 2018

Press release - No. 13/2017

Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January 2018


  • Zealand's management will provide an update on strategy and business
  • Keynote presentations from two key opinion leaders

Copenhagen, Denmark, December 21, 2017 - Zealand announces that it will host a Capital Market Day for investors and analysts in New York on Thursday 25 January 2018 at 12 to 3 pm, followed by an event in Copenhagen on Monday 29 January 2018, where external speakers will not be present.

The Capital Market Days will include an update on the status of Zealand's business and its progress towards becoming a leader in specialty gastrointestinal and metabolic diseases. Management will present the progress and outlook for glepaglutide for the treatment of short bowel syndrome and dasiglucagon for diabetes care and treatment of congenital hyperinsulinsm (CHI) as well as an update on the strong research pipeline.

In addition, we are proud to present two external speakers:

  • David F. Mercer, M.D., Ph.D., associate professor in the UNMC Department of Surgery-Transplant and director of Nebraska Medicine's Intestinal Rehabilitation Program, will provide important insights regarding the treatment of short bowel syndrome.
  • Jessica Castle, M.D. will provide a clinician perspective of glucagon. Jessica Castle is as an assistant professor at the Harold Schnitzer Diabetes Health Center, Portland.

Capital Markets Day in New York





Thursday, 25 January 2018

Time: 12:30 - 3:00 pm ET (lunch will be served from 12:00 pm)

Venue: Dechert Law Firm offices, 1095 Avenue of the Americas, at the corner of 42th West facing Bryant Park, New York City


Before end of business Tuesday, 23 January 2018 to Lifesci Advisors on link



Capital Markets Event in Copenhagen







Monday, 29 January 2018


13:30 - 16:00  CET


Zealand Pharma, Smedeland 36, 2600 Glostrup


This event will not be webcasted, but the presentations from the two key opinion leaders from the New York event will be shown.


Before January 26 2018 by mail


For further information, please contact:

Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail:

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim, and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit or follow Zealand on LinkedIn or Twitter @ZealandPharma.